Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer

• 資料種別: 博士論文
• タイトル: Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer
• 著者・編者: Maehana, Tomoka; Kawaguchi, Ryuji; Nishikawa, Kyohei; Kawahara, Naoki; Yamada, Yuki; Kimura, Fuminori
• 著者標目: Maehana, Tomoka; Kawaguchi, Ryuji; Nishikawa, Kyohei; Kawahara, Naoki; Yamada, Yuki; Kimura, Fuminori
• 出版事項: Spandidos Publications
• 出版年月日等: 2024-05
• 出版年（W3CDTF）: 2024-05
• 並列タイトル等: 卵巣癌の予後予測マーカーとしての組織経路インヒビター2の有用性についての検討
• タイトル（掲載誌）: Oncology letters
• 巻号年月日等（掲載誌）: 28 1
• 掲載巻: 28
• 掲載号: 1
• 掲載ページ: 302-
• ISSN（掲載誌）: ISSN : 1792-1082
• 授与機関名: 奈良県立医科大学
• 授与年月日: 2025-03-14
• 報告番号: 甲第962号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: ovarian cancer; ovarian clear cell carcinoma; retrospective study; survival rate; predictive factor; tissue factor pathway inhivitor-2
• 対象利用者: 一般
• 一般注記: 出版タイプ： VoR; type:Thesis; Abstract. Tissue factor pathway inhibitor‑2 (TFPI2) is a tumor marker for diagnosing ovarian cancer and ovarian clear cell carcinoma (OCCC); however, its effectiveness as a prognostic marker remains unclear. The present study aimed to investigate the utility of TFPI2 as a prognostic marker for ovarian cancer. A total of 256 cases of ovarian cancer was collected at Nara Medical University (Kashihara, Japan) from January 2008 to January 2022. The majority of cases were serous carcinoma (109, 42.6%), followed by OCCC (66, 25.8%), mucinous carcinoma (40, 15.6%), endometrial carcinoma (15, 5.9%), and other (26, 10.2%). The median preoperative serum TFPI2 for ovarian cancer was 219.0 (82.5‑5,824.2) pg/ml. Overall survival (OS) of patients with non‑OCCC and OCCC was calculated using the cut‑off value determined obtained through receiver operating characteristic curve analysis. Cut‑off values of TFPI2 for OS were 201 for non‑OCCC and 255 pg/ml for OCCC. In univariate analysis, OS was significantly elevated in patients with non‑OCCC and OCCC who had TFPI2 levels ≥201 pg/ml (P<0.001) and ≥255 pg/ml (P=0.036), respectively. Progression‑free survival (PFS) was significantly elevated in patients with non‑OCCC and OCCC who had TFPI2 levels ≥201 and ≥255 pg/ml (both P<0.001), respectively. Multivariate analysis revealed that OS was significantly higher in patients with non‑OCCC who had TFPI2 levels ≥201 pg/ml (P=0.021), while PFS was significantly higher in patients with OCCC who had TFPI2 levels ≥255 pg/ml (P=0.020). These findings suggest that TFPI2 is a potential prognostic marker for ovarian carcinoma.; 権利情報：© Maehana et al. This work is licensed under a Creative Commons Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. https://creativecommons.org/licenses/by-nc-nd/4.0/; identifier:Oncology letters. 2024 May, vol.28, no.1, article no.302; identifier:1792-1082; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4457; identifier:Oncology letters, 28(1): 302
• 一次資料へのリンクURL: fulltext; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4457/6/01%e7%94%b2962%e6%9c%ac%e6%96%87.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4457/1/02%e7%94%b2962%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4457/2/03%e7%94%b2962%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.3892/ol.2024.14435; https://doi.org/10.3892/ol.2024.14435
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU